Friday, 18 September 2020


Temasek backs $90M funding for JW Therapeutics

10 March 2018 | News

The latest financing will help the team further advance the JWCAR029 clinical programme.

Image credit- cio.com

Image credit- cio.com

A consortium of leading global investors including Temasek and Sequoia Capital China has joined the $90-million Series A financing round of Shanghai-based biotech startup JW Therapeutics.

Others investors who joined the round include YuanMing Capital, Oriza Seed Capital, Yipu Capital, AVICT Global Holdings. Existing investors WuXi AppTec Group and Juno Therapeutics also participated in the round.

The latest financing will help the team further advance the JWCAR029 clinical programme, develop a therapeutic pipeline and build a new commercial manufacturing facility.


THe startup mainly focuses on leading cell-based therapy technologies. JW Therapeutics’ recent developments include JWCAR029, a CAR-T therapy (emerging form of cancer treatment, primarily for blood cancers like leukaemia) for treatment of B-cell (a type of white blood cell) malignancies.



Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account




Podcast

 

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls